PASG · Passage BIO, Inc. · Executive Compensation
$4.01
+0.01 (+0.25%)
At close · Nov 12
Return incl. dividend (before tax)
Q4 2022 earnings call transcript
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, there is substantial doubt about the Company's ability to continue as a going concern within one year after the date that these consolidated financial statements are issued.”View the 10-Q filed Aug 10, 2026
Market Cap
$12.90M
Shares
3.22M
Volume · Nov 12
12.63K
Avg daily vol (3M)
20.62K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Athena Countouriotis | member of the Audit Committee | Appointed | 2025-09-18 |
| Saqib Islam | member of the Board of Directors | Resigned | 2025-09-18 |
| Thomas Kassberg | Class I director and as a member of the Audit Committee of the Board | Appointed | 2024-09-10 |
| Susan Browne, Ph.D. | Chief Scientific Officer | Appointed | 2024-08-01 |
| Stuart Henderson | Chief Business Officer | Appointed | 2024-08-01 |
| Mark Forman, M.D., Ph.D. | Chief Medical Officer | Resigned | 2024-08-01 |
| Kathleen Borthwick | Chief Financial Officer | Appointed | 2024-03-04 |
| Dolan Sondhi | Class II director | Appointed | 2023-07-31 |
| Thomas Woiwode, Ph.D. | Board of Directors | Resigned | 2023-07-31 |
| Kathleen Borthwick | Senior Vice President and Interim Chief Financial Officer | Appointed | 2023-07-20 |
| Edgar B. (Chip) Cale | Interim Chief Executive Officer | Resigned | 2022-10-11 |
| William Chou, M.D. | member of the Board | Appointed | 2022-10-11 |
| William Chou, M.D. | Chief Executive Officer | Appointed | 2022-10-11 |
| Dr. Michael Kamarck | Class I director | Appointed | 2022-07-06 |
Leadership
- Peter Smith, Ph.D. CEO
- William Chou CEO, Board Member
- William Chou, M.D. CEO, Board Member
- Maxine Gowen Chairman
- Kathleen Borthwick CFO
- Athena Countouriotis Board Member
- Dolan Sondhi Board Member
- Dr. Maxine Gowen Board Member
- Dr. Michael Kamarck Board Member
- Thomas Kassberg Board Member
Key facts
CIK
1787297
CUSIP
702712209
13F (30d)
25 filings
14 filers
Visit website
Investor relations